How to approach and treat viral infections in ICU patients

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Kelesidis, Theodoros ^a   Mastoris, Ioannis ^b   Metsini, Aliki ^b   Tsiodras, Sotirios ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CORTICOSTEROID; FAVIPIRAVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; LANINAMIVIR OCTANOATE; OSELTAMIVIR; PALIVIZUMAB; PERAMIVIR; RIBAVIRIN; SIALIDASE INHIBITOR; VALACICLOVIR; ZANAMIVIR;

CARDIOGENIC SHOCK; COMMUNITY ACQUIRED PNEUMONIA; CYTOMEGALOVIRUS; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; ENCEPHALITIS; HEALTH CARE ASSOCIATED PNEUMONIA; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFLUENZA; INFLUENZA A; INFLUENZA VACCINATION; INTENSIVE CARE; LASSA FEVER; LATENT VIRUS INFECTION; MENINGOENCEPHALITIS; PANDEMIC INFLUENZA; PROGNOSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; SEASONAL INFLUENZA; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA; VIRUS ENCEPHALITIS; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS MYOCARDITIS; VIRUS REACTIVATION; ANIMAL; INTENSIVE CARE UNIT; VIRUS DISEASES;

ANIMALS; ANTIVIRAL AGENTS; CRITICAL CARE; HUMANS; INTENSIVE CARE UNITS; VIRUS DISEASES;

EID: 84964312676     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-321     Document Type: Review

References (204)

1. Luyt CE: Virus diseases in ICU patients: a long time underestimated; but be aware of overestimation. Intensive Care Med 2006, 32:968-970.
2. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, Nicoll A, Touch S, Yuen KY: Avian influenza A (H5N1) infection in humans. N Engl J Med 2005, 353:1374-1385.
3. Peiris JS, Yuen KY, Osterhaus AD, Stohr K: The severe acute respiratory syndrome. N Engl J Med 2003, 349:2431-2441.
4. Bruynseels P, Jorens PG, Demey HE, Goossens H, Pattyn SR, Elseviers MM, Weyler J, Bossaert LL, Mentens Y, Ieven M: Herpes simplex virus in the respiratory tract of critical care patients: a prospective study. Lancet 2003, 362:1536-1541.
5. Ong GM, Lowry K, Mahajan S, Wyatt DE, Simpson C, O'Neill HJ, McCaughey C, Coyle PV: Herpes simplex type 1 shedding is associated with reduced hospital survival in patients receiving assisted ventilation in a tertiary referral intensive care unit. J Med Virol 2004, 72:121-125.
6. Luyt CE, Combes A, Deback C, Aubriot-Lorton MH, Nieszkowska A, Trouillet JL, Capron F, Agut H, Gibert C, Chastre J: Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007, 175:935-942.
7. Spaeder MC, Custer JW, Bembea MM, Aganga DO, Song X, Scafidi S: A multicenter outcomes analysis of children with severe viral respiratory infection due to human metapneumovirus. Pediatr Crit Care Med 2013, 14:268-272.
8. Spaeder MC: Severe adenoviral respiratory infection in children. Intensive Care Med 2013, 39:1157-1158.
9. Spaeder MC, Fackler JC: Time series model to predict burden of viral respiratory illness on a pediatric intensive care unit. Med Decis Making 2011, 31:494-499.
10. Ghelani SJ, Spaeder MC, Pastor W, Spurney CF, Klugman D: Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes 2012, 5:622-627.
11. Greenberg SB: Infections in the immunocompromised rheumatologic patient. Crit Care Clin 2002, 18:931-956.
12. Hayden F: Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009, 48(Suppl 1):S3-S13.
13. De Clercq E: A Cutting-Edge View on the Current State of Antiviral Drug Development. Med Res Rev 2013, [in press].
14. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD: T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009, 82:95-102.
15. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL: Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013, 100:446-454.
16. Taber LH, Knight V, Gilbert BE, McClung HW, Wilson SZ, Norton HJ, Thurson JM, Gordon WH, Atmar RL, Schlaudt WR: Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 1983, 72:613-618.
17. De Clercq E: Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives. Med Res Rev 2009, 29:611-645.
18. De Clercq E: The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. Med Res Rev 2011, 31:118-160.
19. Esmonde TF, Herdman G, Anderson G: Chickenpox pneumonia: an association with pregnancy. Thorax 1989, 44:812-815.
20. Hecht DW, Snydman DR, Crumpacker CS, Werner BG, Heinze-Lacey B: Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia. J Infect Dis 1988, 157:187-190.
21. Buckingham SC, Jafri HS, Bush AJ, Carubelli CM, Sheeran P, Hardy RD, Ottolini MG, Ramilo O, DeVincenzo JP: A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis 2002, 185:1222-1228.
22. Gustafson LM, Proud D, Hendley JO, Hayden FG, Gwaltney JM Jr: Oral prednisone therapy in experimental rhinovirus infections. J Allergy Clin Immunol 1996, 97:1009-1014.
23. Puhakka T, Makela MJ, Malmstrom K, Uhari M, Savolainen J, Terho EO, Pulkkinen M, Ruuskanen O: The common cold: effects of intranasal fluticasone propionate treatment. J Allergy Clin Immunol 1998, 101:726-731.
24. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, Gordon S, Guan Y, Peiris JS: Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002, 360:1831-1837.
25. So LK, Lau AC, Yam LY, Cheung TM, Poon E, Yung RW, Yuen KY: Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003, 361:1615-1617.
26. Mer M, Richards GA: Corticosteroids in life-threatening varicella pneumonia. Chest 1998, 114:426-431.
27. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY: Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011, 52:447-456.
28. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, Liu R, Lai KY, Lau CC, Liu SH, Chan KH, Lin CK, Yuen KY: Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection. Chest 2013, 144:464-473.
29. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD: Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988, 109:783-788.
30. Schmidt GM, Kovacs A, Zaia JA, Horak DA, Blume KG, Nademanee AP, O'Donnell MR, Snyder DS, Forman SJ: Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirusassociated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988, 46:905-907.
31. Hussey GD, Klein M: A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med 1990, 323:160-164.
32. Kramer AH: Viral encephalitis in the ICU. Crit Care Clin 2013, 29:621-649.
33. Pyrgos V, Younus F: High-dose steroids in the management of acute flaccid paralysis due to West Nile virus infection. Scand J Infect Dis 2004, 36:509-512.
34. Walid MS, Mahmoud FA: Successful treatment with intravenous immunoglobulin of acute flaccid paralysis caused by west nile virus. Perm J 2009, 13:43-46.
35. Braun LE, Tsuchida T, Spiegel H: Meningoencephalitis in a child complicated by myocarditis, quadriparesis and respiratory failure. Pediatr Infect Dis J 2006, 25:853. 855-856.
36. Hruska JF, Bernstein JM, Douglas RG Jr, Hall CB: Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother 1980, 17:770-775.
37. Chen HS, Wang W, Wu SN, Liu JP: Corticosteroids for viral myocarditis. Cochrane Database Syst Rev 2013, 10:CD004471.
38. Robinson JL, Hartling L, Crumley E, Vandermeer B, Klassen TP: A systematic review of intravenous gamma globulin for therapy of acute myocarditis. BMC Cardiovasc Disord 2005, 5:12.
39. Dennert R, Velthuis S, Schalla S, Eurlings L, van Suylen RJ, van Paassen P, Tervaert JW, Wolffs P, Goossens VJ, Bruggeman C, Waltenberger J, Crijns HJ, Heymans S: Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther 2010, 15:193-201.
40. Wildenbeest JG, Wolthers KC, Straver B, Pajkrt D: Successful IVIG treatment of human parechovirus-associated dilated cardiomyopathy in an infant. Pediatrics 2013, 132:e243-e247.
41. Liu ZL, Liu ZJ, Liu JP, Kwong JS: Herbal medicines for viral myocarditis. Cochrane Database Syst Rev 2013, 8:CD003711.
42. Enria DA, Maiztegui JI: Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 1994, 23:23-31.
43. Jahrling PB, Frame JD, Rhoderick JB, Monson MH: Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg 1985, 79:380-384.
44. Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN: Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991, 164:1119-1127.
45. Sautto G, Mancini N, Gorini G, Clementi M, Burioni R: Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections. Biomed Res Int 2013, 2013:838491.
46. Gould EA, Buckley A, Barrett AD, Cammack N: Neutralizing (54 K) and nonneutralizing (54 K and 48 K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol 1986, 67(Pt 3):591-595.
47. Ray D, Shi PY: Recent advances in flavivirus antiviral drug discovery and vaccine development. Recent Pat Antiinfect Drug Discov 2006, 1:45-55.
48. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB: Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet 1995, 346:472-475.
49. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R: Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986, 314:20-26.
50. De Clercq E: Yet another ten stories on antiviral drug discovery (part D): paradigms, paradoxes, and paraductions. Med Res Rev 2010, 30:667-707.
51. Moleta DB, Kakitani FT, Lima AS, Franca JC, Raboni SM: Acute pancreatitis associated with acute viral hepatitis: case report and review of literature. Rev Inst Med Trop Sao Paulo 2009, 51:349-351.
52. Alevritis EM, Sarubbi FA, Jordan RM, Peiris AN: Infectious causes of adrenal insufficiency. South Med J 2003, 96:888-890.
53. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR: Viral pneumonia. Lancet 2011, 377:1264-1275.
54. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al-Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla AI, Memish ZA: Hospital outbreak of Middle East respiratory syndrome corona virus. N Engl J Med 2013, 369:407-416.
55. Chan PK, Chan MC, Cheung JL, Lee N, Leung TF, Yeung AC, Wong MC, Ngai KL, Nelson EA, Hui DS: Influenza B lineage circulation and hospitalization rates in a subtropical city, Hong Kong, 2000-2010. Clin Infect Dis 2013, 56:677-684.
56. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, Ng TK, Chan KH, Lai ST, Lim WL, Yuen KY, Guan Y: Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004, 363:617-619.
57. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung CB, To KF, Lui SF, Szeto CC, Chung S, Sung JJ: A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003, 348:1986-1994.
58. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG: Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010, 362:1708-1719.
59. Greenberg SB: Viral pneumonia. Infect Dis Clin North Am 1991, 5:603-621.
60. Rello J, Diaz E: Pneumonia in the intensive care unit. Crit Care Med 2003, 31:2544-2551.
61. Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P: Severe communityacquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 1994, 105:1487-1495.
62. de Roux A, Marcos MA, Garcia E, Mensa J, Ewig S, Lode H, Torres A: Viral community-acquired pneumonia in nonimmunocompromised adults. Chest 2004, 125:1343-1351.
63. Diaz A, Barria P, Niederman M, Restrepo MI, Dreyse J, Fuentes G, Couble B, Saldias F: Etiology of community-acquired pneumonia in hospitalized patients in chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest 2007, 131:779-787.
64. Woodhead M: Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl 2002, 36:20s-27s.
65. Jennings LC, Anderson TP, Beynon KA, Chua A, Laing RT, Werno AM, Young SA, Chambers ST, Murdoch DR: Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008, 63:42-48.
66. Doyle JS, Buising KL, Thursky KA, Worth LJ, Richards MJ: Epidemiology of infections acquired in intensive care units. Semin Respir Crit Care Med 2011, 32:115-138.
67. Chiche L, Forel JM, Papazian L: The role of viruses in nosocomial pneumonia. Curr Opin Infect Dis 2011, 24:152-156.
68. Ramsey CD, Kumar A: Influenza and endemic viral pneumonia. Crit Care Clin 2013, 29:1069-1086.
69. Ramsey C, Kumar A: H1N1: viral pneumonia as a cause of acute respiratory distress syndrome. Curr Opin Crit Care 2011, 17:64-71.
70. Sprung CL, Zimmerman JL, Christian MD, Joynt GM, Hick JL, Taylor B, Richards GA, Sandrock C, Cohen R, Adini B: Recommendations for intensive care unit and hospital preparations for an influenza epidemic or mass disaster: summary report of the European Society of Intensive Care Medicine's Task Force for intensive care unit triage during an influenza epidemic or mass disaster. Intensive Care Med 2010, 36:428-443.
71. Osawa R, Singh N: Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care 2009, 13:R68.
72. Luyt CE, Combes A, Nieszkowska A, Trouillet JL, Chastre J: Viral infections in the ICU. Curr Opin Crit Care 2008, 14:605-608.
73. Johnstone J, Majumdar SR, Fox JD, Marrie TJ: Human metapneumovirus pneumonia in adults: results of a prospective study. Clin Infect Dis 2008, 46:571-574.
74. Hall CB, Douglas RG Jr, Geiman JM, Messner MK: Nosocomial respiratory syncytial virus infections. N Engl J Med 1975, 293:1343-1346.
75. Aitken C, Jeffries DJ: Nosocomial spread of viral disease. Clin Microbiol Rev 2001, 14:528-546.
76. Horcajada JP, Pumarola T, Martinez JA, Tapias G, Bayas JM, de la Prada M, Garcia F, Codina C, Gatell JM, Jimenez de Anta MT: A nosocomial outbreak of influenza during a period without influenza epidemic activity. Eur Respir J 2003, 21:303-307.
77. Choi SH, Hong SB, Ko GB, Lee Y, Park HJ, Park SY, Moon SM, Cho OH, Park KH, Chong YP, Kim SH, Huh JW, Sung H, Do KH, Lee SO, Kim MN, Jeong JY, Lim CM, Kim YS, Woo JH, Koh Y: Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 2012, 186:325-332.
78. Daubin C, Vincent S, Vabret A, du Cheyron D, Parienti JJ, Ramakers M, Freymuth F, Charbonneau P: Nosocomial viral ventilator-associated pneumonia in the intensive care unit: a prospective cohort study. Intensive Care Med 2005, 31:1116-1122.
79. Anderson LJ: Major trends in nosocomial viral infections. Am J Med 1991, 91:107S-111S.
80. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA: The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009, 15:496-497.
81. Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013, 13:260-268.
82. Papazian L, Fraisse A, Garbe L, Zandotti C, Thomas P, Saux P, Pierrin G, Gouin F: Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology 1996, 84:280-287.
83. Papazian L, Doddoli C, Chetaille B, Gernez Y, Thirion X, Roch A, Donati Y, Bonnety M, Zandotti C, Thomas P: A contributive result of open-lung biopsy improves survival in acute respiratory distress syndrome patients. Crit Care Med 2007, 35:755-762.
84. Raoult D, Audic S, Robert C, Abergel C, Renesto P, Ogata H, La SB, Suzan M, Claverie JM: The 1.2-megabase genome sequence of Mimivirus. Science 2004, 306:1344-1350.
85. Dare RK, Chittaganpitch M, Erdman DD: Screening pneumonia patients for mimivirus. Emerg Infect Dis 2008, 14:465-467.
86. Berger P, Papazian L, Drancourt M, La SB, Auffray JP, Raoult D: Amebaassociated microorganisms and diagnosis of nosocomial pneumonia. Emerg Infect Dis 2006, 12:248-255.
87. La SB, Marrie TJ, Auffray JP, Raoult D: Mimivirus in pneumonia patients. Emerg Infect Dis 2005, 11:449-452.
88. Raoult D, Renesto P, Brouqui P: Laboratory infection of a technician by mimivirus. Ann Intern Med 2006, 144:702-703.
89. Oud L: Comment on: "Nosocomial viral ventilator-associated pneumonia in the intensive care unit" by Daubin et al. Intensive Care Med 2006, 32:613-615.
90. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E: Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007, 357:1373-1381.
91. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM: Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011, 60:1-24.
92. Centers for Disease Control and Prevention: Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. ; 2014. http://www.cdc.gov/H1N1flu/antiviral.htm. Accessed January 2014. Ref Type: Online Source.
93. Aoki FY, Boivin G, Roberts N: Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007, 12:603-616.
94. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P: Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000, 355:1845-1850.
95. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000, 283:1016-1024.
96. Widmer N, Meylan P, Ivanyuk A, Aouri M, Decosterd LA, Buclin T: Oseltamivir in seasonal, avian H5N1 and pandemic A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin Pharmacokinet 2009, 2010(49):741-765.
97. Davies BE: Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010, 65(Suppl 2):ii5-ii10.
98. Dutkowski R, Smith JR, Davies BE: Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int J Antimicrob Agents 2010, 35:461-467.
99. Lee N, Ison MG: Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther 2012, 17:143-157.
100. Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, Yazdanpanah Y, Beigel J, Chotpitayasunondh T, Del Mar C, Farrar J, Tran TH, Ozbay B, Sugaya N, Fukuda K, Shindo N, Stockman L, Vist GE, Croisier A, Nagjdaliyev A, Roth C, Thomson G, Zucker H, Oxman AD: WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007, 7:21-31.
101. Lee N, Hui DS, Zuo Z, Ngai KL, Lui GC, Wo SK, Tam WW, Chan MC, Wong BC, Wong RY, Choi KW, Sin WW, Lee EL, Tomlinson B, Hayden FG, Chan PK: A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clin Infect Dis 2013, 57:1511-1519.
102. Taylor WR, Thinh BN, Anh GT, Horby P, Wertheim H, Lindegardh N, de Jong MD, Stepniewska K, Hanh TT, Hien ND, Bien NM, Chau NQ, Fox A, Ngoc NM, Crusat M, Farrar JJ, White NJ, Ha NH, Lien TT, Trung NV, Day N, Binh NG: Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One 2008, 3:e3410.
103. Nguyen HT, Fry AM, Gubareva LV: Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther 2012, 17:159-173.
104. McSharry JJ, Weng Q, Brown A, Kulawy R, Drusano GL: Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 2009, 53:2375-2381.
105. Wang D, Sleeman K, Huang W, Nguyen HT, Levine M, Cheng Y, Li X, Tan M, Xing X, Xu X, Klimov AI, Gubareva LV, Shu Y: Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. Antiviral Res 2013, 97:240-244.
106. Garg S, Moore Z, Lee N, McKenna J, Bishop A, Fleischauer A, Springs CB, Nguyen HT, Sheu TG, Sleeman K, Finelli L, Gubareva L, Fry AM: A cluster of patients infected with I221V influenza b virus variants with reduced oseltamivir susceptibility-North Carolina and South Carolina, 2010-2011. J Infect Dis 2013, 207:966-973.
107. Lee N, Wong CK, Chan PK, Lindegardh N, White NJ, Hayden FG, Wong EH, Wong KS, Cockram CS, Sung JJ, Hui DS: Acute encephalopathy associated with influenza A infection in adults. Emerg Infect Dis 2010, 16:139-142.
108. Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B, Boak L, Patel A, Hoffmann G, Prinssen EP, Rayner CR: Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother 2008, 52:3687-3693.
109. South East Asia Infectious Disease Clinical Research Network: Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013, 346:f3039.
110. Lee N, Chan PK, Wong CK, Wong KT, Choi KW, Joynt GM, Lam P, Chan MC, Wong BC, Lui GC, Sin WW, Wong RY, Lam WY, Yeung AC, Leung TF, So HY, Yu AW, Sung JJ, Hui DS: Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther 2011, 16:237-247.
111. Centers for Disease Control and Prevention (CDC): Update: Recommendations for Middle East respiratory syndrome coronavirus (MERS-CoV). MMWR Morb Mortal Wkly Rep 2013, 62:557.
112. Centers for Disease Control and Prevention (CDC): Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients-Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009, 58:893-896.
113. De Clercq E: Antivirals: past, present and future. Biochem Pharmacol 2013, 85:727-744.
114. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, Mishin VP, Hayden FG, Kim DH, Ing A, Campbell ER, Yu M, Fang F: Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006, 50:1470-1479.
115. Smee DF, Hurst BL, Wong MH: Effects of TheraMax on influenza virus infections in cell culture and in mice. Antivir Chem Chemother 2011, 21:231-237.
116. Smee DF, Bailey KW, Wong MH, O'Keefe BR, Gustafson KR, Mishin VP, Gubareva LV: Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res 2008, 80:266-271.
117. Selvam P, Murugesh N, Chandramohan M, Sidwell RW, Wandersee MK, Smee DF: Anti-influenza virus activities of 4-[(1, 2-dihydro-2-oxo-3H-indol-3-ylidene)amino]-N-(4, 6-dimethyl-2-pyrimidin-2-yl) benzenesulphonamide and its derivatives. Antivir Chem Chemother 2006, 17:269-274.
118. Ubillas R, Jolad SD, Bruening RC, Kernan MR, King SR, Sesin DF, Barrett M, Stoddart CA, Flaster T, Kuo J, Ayala F, Meza E, Castanel M, McMeekin D, Rozhon E, Tempesta MS, Barnard D, Huffman J, Smee D, Sidwell R, Soike K, Brazier A, Safrin S, Orlando R, Kenny PT, Berova N, Nakanishi K: SP-303, an antiviral oligomeric proanthocyanidin from the latex of Croton lechleri (Sangre de Drago). Phytomedicine 1994, 1:77-106.
119. Shigeta S, Mori S, Kodama E, Kodama J, Takahashi K, Yamase T: Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates. Antiviral Res 2003, 58:265-271.
120. Shigeta S, Mori S, Yamase T, Yamamoto N, Yamamoto N: Anti-RNA virus activity of polyoxometalates. Biomed Pharmacother 2006, 60:211-219.
121. Ono L, Wollinger W, Rocco IM, Coimbra TL, Gorin PA, Sierakowski MR: In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (BeH111 strain) and dengue 1 virus (Hawaii strain). Antiviral Res 2003, 60:201-208.
122. Krajczyk A, Kulinska K, Kulinski T, Hurst BL, Day CW, Smee DF, Ostrowski T, Januszczyk P, Zeidler J: Antivirally active ribavirin analogues-4, 5-disubstituted 1, 2, 3-triazole nucleosides: biological evaluation against certain respiratory viruses and computational modelling. Antivir Chem Chemother 2014, 23:161-171.
123. Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF: In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 2005, 68:10-17.
124. Smee DF, Wandersee MK, Wong MH, Bailey KW, Sidwell RW: Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine. Antivir Chem Chemother 2004, 15:261-268.
125. Gilbert BE, Wilson SZ, Knight V, Couch RB, Quarles JM, Dure L, Hayes N, Willis G: Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother 1985, 27:309-313.
126. Huggins J, Zhang ZX, Bray M: Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis 1999, 179(Suppl 1):S240-S247.
127. Tam RC, Lau JY, Hong Z: Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother 2001, 12:261-272.
128. Sookoian S, Castano G, Flichman D, Cello J: Effects of ribavirin on cytokine production of recall antigens and phytohemaglutinin-stimulated peripheral blood mononuclear cells. (Inhibitory effects of ribavirin on cytokine production). Ann Hepatol 2004, 3:104-107.
129. Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL: In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Res 2011, 92:329-340.
130. Smee DF, Hurst BL, Day CW: D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother 2012, 22:263-272.
131. Wunderlich K, Juozapaitis M, Ranadheera C, Kessler U, Martin A, Eisel J, Beutling U, Frank R, Schwemmle M: Identification of high-affinity PB1-derived peptides with enhanced affinity to the PA protein of influenza A virus polymerase. Antimicrob Agents Chemother 2011, 55:696-702.
132. Manz B, Gotz V, Wunderlich K, Eisel J, Kirchmair J, Stech J, Chase G, Frank R, Schwemmle M: Disruption of the viral polymerase complex assembly as a novel approach to attenuate influenza A virus. J Biol Chem 2011, 286:8414-8424.
133. Gerritz SW, Cianci C, Kim S, Pearce BC, Deminie C, Discotto L, McAuliffe B, Minassian BF, Shi S, Zhu S, Zhai W, Pendri A, Li G, Poss MA, Edavettal S, McDonnell PA, Lewis HA, Maskos K, Mortl M, Kiefersauer R, Steinbacher S, Baldwin ET, Metzler W, Bryson J, Healy MD, Philip T, Zoeckler M, Schartman R, Sinz M, Leyva-Grado VH, et al: Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci U S A 2011, 108:15366-15371.
134. Kao RY, Yang D, Lau LS, Tsui WH, Hu L, Dai J, Chan MP, Chan CM, Wang P, Zheng BJ, Sun J, Huang JD, Madar J, Chen G, Chen H, Guan Y, Yuen KY: Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010, 28:600-605.
135. McCown M, Diamond MS, Pekosz A: The utility of siRNA transcripts produced by RNA polymerase i in down regulating viral gene expression and replication of negative-and positive-strand RNA viruses. Virology 2003, 313:514-524.
136. Barik S: siRNA for Influenza Therapy. Viruses 2010, 2:1448-1457.
137. Truong NP, Gu W, Prasadam I, Jia Z, Crawford R, Xiao Y, Monteiro MJ: An influenza virus-inspired polymer system for the timed release of siRNA. Nat Commun 2013, 4:1902.
138. Mollaie HR, Monavari SH, Arabzadeh SA, Shamsi-Shahrabadi M, Fazlalipour M, Afshar RM: RNAi and miRNA in Viral Infections and Cancers. Asian Pac J Cancer Prev 2013, 14:7045-7056.
139. Rossignol JF, La FS, Chiappa L, Ciucci A, Santoro MG: Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009, 284:29798-29808.
140. Maddry JA, Chen X, Jonsson CB, Ananthan S, Hobrath J, Smee DF, Noah JW, Noah D, Xu X, Jia F, Maddox C, Sosa MI, White EL, Severson WE: Discovery of novel benzoquinazolinones and thiazoloimidazoles, inhibitors of influenza H5N1 and H1N1 viruses, from a cell-based high-throughput screen. J Biomol Screen 2011, 16:73-81.
141. Rao JR, Jha AK, Rawal RK, Sharon A, Day CW, Barnard DL, Smee DF, Chu CK: (-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu). Bioorg Med Chem Lett 2009, 2010(20):2601-2604.
142. Selvam P, Chandramohan M, Hurst BL, Smee DF: Activity of isatinesulfadimidine derivatives against 2009 pandemic H1N1 influenza virus in cell culture. Antivir Chem Chemother 2010, 20:143-146.
143. Selvam P, Vijayalakshimi P, Smee DF, Gowen BB, Julander JG, Day CW, Barnard DL: Novel 3-sulphonamido-quinazolin-4(3H)-one derivatives: microwave-assisted synthesis and evaluation of antiviral activities against respiratory and biodefense viruses. Antivir Chem Chemother 2007, 18:301-305.
144. Smee DF, McKernan PA, Nord LD, Willis RC, Petrie CR, Riley TM, Revankar GR, Robins RK, Smith RA: Novel pyrazolo[3, 4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity. Antimicrob Agents Chemother 1987, 31:1535-1541.
145. Lai KY, Ng WY, Osburga Chan PK, Wong KF, Cheng F: High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. Ann Intern Med 2010, 152:687-688.
146. Garozzo A, Tempera G, Ungheri D, Timpanaro R, Castro A: N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int J Immunopathol Pharmacol 2007, 20:349-354.
147. Mata M, Morcillo E, Gimeno C, Cortijo J: N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol 2011, 82:548-555.
148. Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl J Jr: Nacetyl-L-cysteine (NAC) inhibits virus replication and expression of proinflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol 2010, 79:413-420.
149. Murray JL, McDonald NJ, Sheng J, Shaw MW, Hodge TW, Rubin DH, O'Brien WA, Smee DF: Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis. Antivir Chem Chemother 2012, 22:205-215.
150. Takeda S, Munakata R, Abe S, Mii S, Suzuki M, Kashiwada T, Azuma A, Yamamoto T, Gemma A, Tanaka K: Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intensive Care Med 2010, 36:906-907.
151. Patel P, Nandwani V, Vanchiere J, Conrad SA, Scott LK: Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A-an associated respiratory failure and hemodynamic shock. Pediatr Crit Care Med 2011, 12:e87-e89.
152. Chong JL, Sapari S, Kuan YC: A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G. J Microbiol Immunol Infect 2011, 44:319-322.
153. Kubota-Koketsu R, Yunoki M, Okuno Y, Ikuta K: Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010. Biologics 2012, 6:245-247.
154. Nath A, Tyler KL: Novel approaches and challenges to treatment of central nervous system viral infections. Ann Neurol 2013, 74:412-422.
155. Yasuda S, Huffman JH, Smee DF, Sidwell RW, Miyata K: Spectrum of virus inhibition by consensus interferon YM643. Antivir Chem Chemother 2000, 11:337-341.
156. Morales DJ, Lenschow DJ: The antiviral activities of ISG15. J Mol Biol 2013, 425:4995-5008.
157. Radigan KA, Urich D, Misharin AV, Chiarella SE, Soberanes S, Gonzalez A, Perlman H, Wunderink RG, Budinger GR, Mutlu GM: The effect of rosuvastatin in a murine model of influenza A infection. PLoS One 2012, 7:e35788.
158. Kumaki Y, Morrey JD, Barnard DL: Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice. Future Virol 2012, 7:801-818.
159. Kwong JC, Li P, Redelmeier DA: Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One 2009, 4:e8087.
160. Makris D, Manoulakas E, Komnos A, Papakrivou E, Tzovaras N, Hovas A, Zintzaras E, Zakynthinos E: Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med 2011, 39:2440-2446.
161. Yamaya M, Shinya K, Hatachi Y, Kubo H, Asada M, Yasuda H, Nishimura H, Nagatomi R: Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther 2010, 333:81-90.
162. Viasus D, Pano-Pardo JR, Cordero E, Campins A, Lopez-Medrano F, Villoslada A, Farinas MC, Moreno A, Rodriguez-Bano J, Oteo JA, Martinez-Montauti J, Torre-Cisneros J, Segura F, Carratala J: Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 2011, 62:193-199.
163. Martin-Loeches I, Bermejo-Martin JF, Valles J, Granada R, Vidaur L, Vergara-Serrano JC, Martin M, Figueira JC, Sirvent JM, Blanquer J, Suarez D, Artigas A, Torres A, Diaz E, Rodriguez A: Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med 2013, 39:693-702.
164. Ishii H, Komiya K, Yamagata E, Yatera K, Chojin Y, Yamamoto H, Mukae H, Kadota J: Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection. J Infect 2012, 64:343-345.
165. Budd A, Alleva L, Alsharifi M, Koskinen A, Smythe V, Mullbacher A, Wood J, Clark I: Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007, 51:2965-2968.
166. Bauer CM, Zavitz CC, Botelho FM, Lambert KN, Brown EG, Mossman KL, Taylor JD, Stampfli MR: Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS One 2010, 5:e13251.
167. Aldridge JR Jr, Moseley CE, Boltz DA, Negovetich NJ, Reynolds C, Franks J, Brown SA, Doherty PC, Webster RG, Thomas PG: TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A 2009, 106:5306-5311.
168. Pitocco D, Giubilato S, Zaccardi F, Di SE, Buffon A, Biasucci LM, Liuzzo G, Crea F, Ghirlanda G: Pioglitazone reduces monocyte activation in type 2 diabetes. Acta Diabetol 2009, 46:75-77.
169. Moseley CE, Webster RG, Aldridge JR: Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respir Vir 2010, 4:307-311.
170. Carey MA, Bradbury JA, Seubert JM, Langenbach R, Zeldin DC, Germolec DR: Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol 2005, 175:6878-6884.
171. Carey MA, Bradbury JA, Rebolloso YD, Graves JP, Zeldin DC, Germolec DR: Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS One 2010, 5:e11610.
172. Lee SM, Gai WW, Cheung TK, Peiris JS: Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro. Antiviral Res 2011, 91:330-334.
173. Lee SM, Gai WW, Cheung TK, Peiris JS: Antiviral activity of a selective COX-2 inhibitor NS-398 on avian influenza H5N1 infection. Influenza Other Respir Vir 2011, 5(Suppl 1):230-232.
174. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, Zhang HJ, Chen HL, Wong SS, Lau SK, Woo PC, Chan KH, Jin DY, Yuen KY: Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A 2008, 105:8091-8096.
175. Aspord C, Laurin D, Richard MJ, Vie H, Chaperot L, Plumas J: Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases. Am J Transplant 2011, 11:2613-2626.
176. Wu CC, Hayashi T, Takabayashi K, Sabet M, Smee DF, Guiney DD, Cottam HB, Carson DA: Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci U S A 2007, 104:3990-3995.
177. Sidwell RW, Smee DF, Huffman JH, Bailey KW, Warren RP, Burger RA, Penney CL: Antiviral activity of an immunomodulatory lipophilic desmuramyl dipeptide analog. Antiviral Res 1995, 26:145-159.
178. Hayden FG, Douglas RG Jr, Simons R: Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother 1980, 18:536-541.
179. Wilson SZ, Knight V, Wyde PR, Drake S, Couch RB: Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother 1980, 17:642-648.
180. Galegov GA, Pushkarskaya NL, Obrosova-Serova NP, Zhdanov VM: Combined action of ribovirin and rimantadine in experimental myxovirus infection. Experientia 1977, 33:905-906.
181. Bantia S, Kellogg D, Parker CD, Babu YS: Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model. Antiviral Res 2010, 88:276-280.
182. Govorkova EA, Fang HB, Tan M, Webster RG: Neuraminidase inhibitorrimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 2004, 48:4855-4863.
183. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA: Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 2007, 12:363-370.
184. Smee DF, Wong MH, Bailey KW, Sidwell RW: Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother 2006, 17:185-192.
185. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA: Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 2008, 52:3889-3897.
186. Smee DF, Bailey KW, Morrison AC, Sidwell RW: Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002, 48:88-93.
187. Smee DF, Hurst BL, Wong MH, Tarbet EB, Babu YS, Klumpp K, Morrey JD: Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res 2010, 88:38-44.
188. Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A, Enouf V, Charlois-Ou C, Vincent C, Andreoletti L, Tubach F, Lina B, Mentre F, Leport C: Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010, 7:e1000362.
189. Hoopes JD, Driebe EM, Kelley E, Engelthaler DM, Keim PS, Perelson AS, Rong L, Went GT, Nguyen JT: Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS One 2011, 6:e29778.
190. Nguyen JT, Smee DF, Barnard DL, Julander JG, Gross M, de Jong MD, Went GT: Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One 2012, 7:e31006.
191. Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, Faix DJ, Blair PJ, de Jong MD, Prichard MN, Went GT: Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5:e9332.
192. Nguyen JT, Hoopes JD, Smee DF, Prichard MN, Driebe EM, Engelthaler DM, Le MH, Keim PS, Spence RP, Went GT: Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009, 53:4115-4126.
193. Tarbet EB, Vollmer AH, Hurst BL, Barnard DL, Furuta Y, Smee DF: In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus. Arch Virol 2014, 159(6):1279-1291.
194. Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD, Smee DF: Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res 2012, 94:103-110.
195. Smee DF, Hurst BL, Wong MH, Bailey KW, Tarbet EB, Morrey JD, Furuta Y: Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 2010, 54:126-133.
196. Smee DF, von Itzstein M, Bhatt B, Tarbet EB: Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs. Antimicrob Agents Chemother 2012, 56:6328-6333.
197. Lat A, Bhadelia N, Miko B, Furuya EY, Thompson GR III: Invasive aspergillosis after pandemic (H1N1) 2009. Emerg Infect Dis 2010, 16:971-973.
198. Zhou B, Zhong N, Guan Y: Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007, 357:1450-1451.
199. Liu P, Martino T, Opavsky MA, Penninger J: Viral myocarditis: balance between viral infection and immune response. Can J Cardiol 1996, 12:935-943.
200. De Clercq E: Antiviral drug discovery: ten more compounds, and ten more stories (part B). Med Res Rev 2009, 29:571-610.
201. Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S: Antiviral activity of a smallmolecule inhibitor of filovirus infection. Antimicrob Agents Chemother 2010, 54:2152-2159.
202. Cote M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J: Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011, 477:344-348.
203. Tomlinson B, Cockram C: SARS: experience at Prince of Wales Hospital, Hong Kong. Lancet 2003, 361:1486-1487.
204. Seto WH, Tsang D, Yung RW, Ching TY, Ng TK, Ho M, Ho LM, Peiris JS: Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 2003, 361:1519-1520.